Phase 2 Mesothelioma Trial, Recruiting NCT06057935 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT06057935
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (any sex)
  • You have been diagnosed with a type of cancer called malignant peritoneal mesothelioma (MPM) at the enrolling hospital
  • During surgery, a tissue sample has confirmed your mesothelioma is the "epithelioid" type (a specific subtype)
  • Surgeons were able to remove all or almost all of the cancer during your procedure
  • You are planning to have surgery to remove all the cancer spread inside the abdomen
  • You are generally active and able to care for yourself, with only minor limitations on strenuous activity (confirm with trial site)
  • Your blood cell counts are within an acceptable range — enough white blood cells and platelets
  • Your kidneys are working well enough (based on a blood or urine test)
  • Your liver is working well enough (based on a blood test)
  • If you are a woman who could become pregnant, you have a negative pregnancy test and agree to use effective contraception throughout the study
  • If you are a man, you agree to use a reliable barrier method of contraception (such as a condom) for the duration of the study
  • You are willing and able to sign a consent form before any study procedures begin

Who may not be able to join:

  • You have previously received chemotherapy given directly into the abdomen or through the bloodstream for peritoneal mesothelioma
  • You have previously received chemotherapy containing platinum-based drugs (such as cisplatin or carboplatin)
  • Your biopsy showed a different subtype of mesothelioma (sarcomatoid, well-differentiated papillary, or benign multicystic)
  • You have had another cancer in the past, unless it was certain skin cancers, a fully treated cervical cancer in situ, another cancer with no signs of activity for more than three years, or a very slow-growing cancer being monitored (confirm with trial site)
  • There is a strong suspicion the cancer has spread outside the abdomen
  • You are pregnant or breastfeeding
  • You have active heart artery disease (such as unstable chest pain or a recent abnormal heart stress test) — though those with a history of heart disease may still qualify with a recent normal stress test or a cardiologist's clearance
  • You have uncontrolled high blood pressure (above 140/90) that has not been cleared for surgery
  • You have moderate-to-severe heart failure or breathing problems that would make participation unsafe or difficult
  • You have a history of stroke or other brain blood vessel disease that would make participation unsafe or difficult
  • You have other serious health conditions unrelated to your cancer that would make full participation unsafe or difficult
  • You have a known allergy to cisplatin, carboplatin, pemetrexed, or mitomycin (chemotherapy drugs used in the trial)
  • At the time of surgery, extensive internal scarring (adhesions) prevents chemotherapy from being delivered inside the abdomen
  • Any other condition that would prevent the chemotherapy from being safely given inside the abdomen
  • You take an oral medication that cannot be substituted and that would be unsafe to stop for up to ten days
  • Your life expectancy is estimated to be less than 12 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Garrett Nash, MD, Memorial Sloan Kettering Cancer

Phone: 212-639-8668

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 September 2023
Est. completion
21 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov